AcelRx Pharmaceuticals, Inc. Securities Litigation (2021)

Filing Deadline: August 09, 2021

If you purchased a significant amount of shares of AcelRx Pharmaceuticals Inc. Common Stock (NASDAQ: ACRX), you have certain options. Investors should contact us before August 09, 2021.

 

Lawsuit Overview

Defendant:AcelRx Pharmaceuticals Inc. Common Stock
Date Filed:June 8th, 2021
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:March 17th, 2020
Class End Date:February 12th, 2021

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA; (ii) as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays; (iii) the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for AcelRx Pharmaceuticals Inc. Common Stock

 
First Identified Complaint

Aaron Sneed Jr., et al. v. AcelRx Pharmaceuticals, Inc., et al.

Date Filed:June 8th, 2021
Class Period Start:March 17th, 2020
Class Period End:February 12th, 2021
First Identified Complaint Filings
#Document TitleFiling Date